Facts of Atriance 5 mg/ml solution for infusion ?
- Medicine Name: Atriance®
- Date of Approval: 22.08.2007
- Company Name: Novartis Europharm Limited
What is Atriance ?
ATRIANCE ® (nelarabine) is indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Approval is based on the unconfirmed surrogate endpoint of clinical response only.
What is Atriance used for?
Atriance is used to treat patients with T-cell acute lymphoblastic leukaemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL). These are types of cancer where T-lymphoblasts (a type of immature white blood cell) multiply too quickly. In T-ALL the abnormal cells are mainly in the blood and bone marrow, and in T-LBL they are mainly in the lymphatic system (lymph nodes or thymus gland). Atriance is used when patients have failed to respond to, or have stopped responding to, at least two types of chemotherapy.
The medicine can only be obtained with a prescription.
How supplied/storage and handling ?
Atriance solution for infusion is a clear, colourless solution. It is provided in clear glass vials with a rubber stopper and sealed with an aluminium cap.
Each vial contains 50 ml.
Atriance is supplied in packs of 6 vials.